CA2729306C - Notch-binding agents and antagonists and methods of use thereof - Google Patents

Notch-binding agents and antagonists and methods of use thereof Download PDF

Info

Publication number
CA2729306C
CA2729306C CA2729306A CA2729306A CA2729306C CA 2729306 C CA2729306 C CA 2729306C CA 2729306 A CA2729306 A CA 2729306A CA 2729306 A CA2729306 A CA 2729306A CA 2729306 C CA2729306 C CA 2729306C
Authority
CA
Canada
Prior art keywords
antibody
seq
human
certain embodiments
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2729306A
Other languages
English (en)
French (fr)
Other versions
CA2729306A1 (en
Inventor
Austin L. Gurney
Timothy Charles Hoey
Edward Thein Htun Van Der Horst
Aaron Ken Sato
Yuan Ching Liu
Maureen Fitch Bruhns
John A. Lewicki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncomed Pharmaceuticals Inc
Original Assignee
Oncomed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharmaceuticals Inc filed Critical Oncomed Pharmaceuticals Inc
Publication of CA2729306A1 publication Critical patent/CA2729306A1/en
Application granted granted Critical
Publication of CA2729306C publication Critical patent/CA2729306C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2729306A 2008-07-08 2009-07-08 Notch-binding agents and antagonists and methods of use thereof Expired - Fee Related CA2729306C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7909508P 2008-07-08 2008-07-08
US61/079,095 2008-07-08
US11269908P 2008-11-07 2008-11-07
US11270108P 2008-11-07 2008-11-07
US61/112,701 2008-11-07
US61/112,699 2008-11-07
PCT/US2009/003994 WO2010005566A2 (en) 2008-07-08 2009-07-08 Notch-binding agents and antagonists and methods of use thereof

Publications (2)

Publication Number Publication Date
CA2729306A1 CA2729306A1 (en) 2010-01-14
CA2729306C true CA2729306C (en) 2015-08-18

Family

ID=41507637

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2729306A Expired - Fee Related CA2729306C (en) 2008-07-08 2009-07-08 Notch-binding agents and antagonists and methods of use thereof
CA2729602A Abandoned CA2729602A1 (en) 2008-07-08 2009-07-08 Notch1 receptor binding agents and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2729602A Abandoned CA2729602A1 (en) 2008-07-08 2009-07-08 Notch1 receptor binding agents and methods of use thereof

Country Status (31)

Country Link
US (11) US8435513B2 (OSRAM)
EP (4) EP2307051B1 (OSRAM)
JP (2) JP5560271B2 (OSRAM)
KR (2) KR101682490B1 (OSRAM)
CN (3) CN104402998A (OSRAM)
AU (2) AU2009269095B2 (OSRAM)
BR (2) BRPI0914007A2 (OSRAM)
CA (2) CA2729306C (OSRAM)
CO (2) CO6390041A2 (OSRAM)
CR (1) CR20110069A (OSRAM)
CY (2) CY1116195T1 (OSRAM)
DK (2) DK2307459T3 (OSRAM)
DO (2) DOP2011000004A (OSRAM)
EA (2) EA026109B1 (OSRAM)
ES (2) ES2531541T3 (OSRAM)
HR (2) HRP20150256T1 (OSRAM)
IL (2) IL210221A (OSRAM)
MA (2) MA32449B1 (OSRAM)
ME (2) ME02148B (OSRAM)
MX (2) MX2011000236A (OSRAM)
MY (2) MY159815A (OSRAM)
NZ (2) NZ590127A (OSRAM)
PL (2) PL2307051T3 (OSRAM)
PT (2) PT2307459E (OSRAM)
RS (2) RS53750B1 (OSRAM)
SG (2) SG192467A1 (OSRAM)
SI (2) SI2307459T1 (OSRAM)
SM (2) SMT201500047B (OSRAM)
UA (1) UA101672C2 (OSRAM)
WO (2) WO2010005567A2 (OSRAM)
ZA (2) ZA201009280B (OSRAM)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2007136856A2 (en) * 2006-05-19 2007-11-29 The Johns Hopkins University Heyl as a therapeutic target and a diagnostic marker for neoplasia and uses therefor
CA2655362A1 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
TWI419904B (zh) 2006-12-18 2013-12-21 Genentech Inc 拮抗劑抗-ｎｏｔｃｈ３抗體及其用於預防及治療ｎｏｔｃｈ３相關疾病之用途
AU2008209482B2 (en) 2007-01-24 2014-05-01 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
NZ590127A (en) 2008-07-08 2012-11-30 Oncomed Pharm Inc Notch1 receptor binding agents and methods of use thereof
US8834875B2 (en) 2010-01-13 2014-09-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
PE20120080A1 (es) * 2008-10-01 2012-02-17 Genentech Inc Anticuerpos anti-notch2 y metodos de uso
WO2010146550A1 (en) 2009-06-18 2010-12-23 Pfizer Inc. Anti notch-1 antibodies
RU2012117619A (ru) * 2009-09-30 2013-11-10 Дженентек, Инк. ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3
ES2895226T3 (es) 2009-10-16 2022-02-18 Mereo Biopharma 5 Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
CN102781316B (zh) 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
BR112012028010A2 (pt) * 2010-05-03 2017-09-26 Genentech Inc anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
WO2012080926A2 (en) 2010-12-15 2012-06-21 Wyeth Llc Anti-notch1 antibodies
US20130058947A1 (en) * 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013039859A1 (en) * 2011-09-12 2013-03-21 Gray Lloyd S Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
PT2758073T (pt) 2011-09-23 2019-02-01 Oncomed Pharm Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
TW201329105A (zh) * 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York 人類ｎｏｔｃｈ１引誘物
US9663573B2 (en) 2011-10-05 2017-05-30 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
CN104105702B (zh) * 2011-11-16 2016-11-23 昂考梅德药品有限公司 人notch受体突变及其应用
KR101535219B1 (ko) * 2011-11-18 2015-07-09 한국생명공학연구원 Ｎｏｔｃｈ３에 대한 인간 단일클론항체
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
WO2013173542A1 (en) * 2012-05-16 2013-11-21 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch2/3 antibodies
KR20200143502A (ko) 2012-08-13 2020-12-23 제넨테크, 인크. 항-jagged 항체 및 사용 방법
AU2013312305B2 (en) 2012-09-07 2018-06-28 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
AU2013317886A1 (en) * 2012-09-21 2015-04-09 Oncomed Pharmaceuticals, Inc. Methods of treating hematological malignancies with NOTCH1 antibodies
CN104797264A (zh) * 2012-10-09 2015-07-22 桑比欧公司 用于治疗视网膜变性的方法和组合物
EP2914961A4 (en) 2012-10-31 2016-04-20 Oncomed Pharm Inc METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
BR112015010436A2 (pt) * 2012-11-07 2017-08-22 Pfizer Anticorpos anti-notch3 e conjugados anticorpo-fármaco
PL2935330T3 (pl) 2012-12-19 2019-11-29 Aveo Pharmaceuticals Inc Przeciwciała przeciw notch3
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
AU2014218290B2 (en) * 2013-02-18 2020-03-12 The Hospital For Sick Children Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells
EP2970468B1 (en) 2013-03-13 2021-07-07 Novartis AG Notch2 binding molecules for treating respiratory diseases
EP2970479B1 (en) * 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
WO2014151606A2 (en) * 2013-03-15 2014-09-25 Oncomed Pharmaceuticals, Inc. Methods of treating pancreatic cancer
JP6527132B2 (ja) * 2013-03-15 2019-06-05 ジェネンテック， インコーポレイテッド 肝臓がんの診断及び治療のための組成物及び方法
JP6571115B2 (ja) 2014-02-12 2019-09-04 ジェネンテック， インコーポレイテッド 抗ｊａｇｇｅｄ１抗体及び使用方法
WO2015153997A2 (en) * 2014-04-04 2015-10-08 Oncomed Pharmaceuticals, Inc. Notch3 antibodies and uses thereof
MX2017000363A (es) 2014-07-11 2017-04-27 Genentech Inc Inhibicion de la via de notch.
GB201416832D0 (en) * 2014-09-24 2014-11-05 Glaxosmithkline Plc Methods of treatment
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
AU2015338974B2 (en) * 2014-10-31 2021-08-26 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN105986001B (zh) * 2015-02-12 2019-12-03 上海交通大学 一种基于膜结合蛋白和荧光互补的高通量猎物拮抗剂筛选方法
WO2016138034A1 (en) * 2015-02-24 2016-09-01 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
MX381139B (es) * 2015-04-16 2025-03-12 Eisai R&D Man Co Ltd Anticuerpo anti-notch4 humano.
HK1255694A1 (zh) * 2015-07-24 2019-08-23 Oncotracker, Inc. 用於治疗免疫系统功能障碍的γ分泌酶调节剂
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
CN115010808A (zh) * 2016-03-16 2022-09-06 阿贝奥姆公司 针对il-25的中和单克隆抗体及其用途
EP3448420B1 (en) 2016-04-29 2022-09-14 Aveo Pharmaceuticals, Inc. Anti-notch3 antibody
WO2017193059A1 (en) 2016-05-06 2017-11-09 The Regents Of The University Of California Systems and methods for targeting cancer cells
US11026996B2 (en) * 2016-05-25 2021-06-08 The Trustees Of Columbia University In The City Of New York Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
SG10201913583QA (en) 2016-08-23 2020-02-27 Univ California Proteolytically cleavable chimeric polypeptides and methods of use thereof
CN110167584B (zh) * 2016-11-07 2024-06-07 威斯塔解剖学和生物学研究所 用于针对莱姆病的dna抗体构建体
WO2018183216A1 (en) 2017-03-27 2018-10-04 The Schepens Eye Research Institute, Inc. Notch3 agonist compositions and methods for treating small vessel diseases
WO2018183213A1 (en) 2017-03-27 2018-10-04 The Schepens Eye Research Institute, Inc. Blood biomarkers and diagnostic methods for small vessel diseases
US11325957B2 (en) * 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
CN107557343B (zh) * 2017-08-09 2020-09-25 苏州大学附属儿童医院 抗人dll4单克隆抗体3f9
EP3743057A4 (en) 2018-01-26 2021-11-17 Massachusetts Eye & Ear Infirmary TREATMENT OF HEARING LOSS
KR20210008840A (ko) * 2018-04-10 2021-01-25 스티흐팅 산퀸 불드포르지닝 키메라 노치 수용체
CN113227128B (zh) * 2018-07-20 2024-06-21 香港理工大学 针对抑制jag1-notch1信号通路的肽
US12016885B2 (en) * 2018-11-06 2024-06-25 Alsatech, Inc. Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab
CN111334575A (zh) * 2020-02-18 2020-06-26 至本医疗科技（上海）有限公司 Notch家族基因变异在预测实体瘤患者对免疫检查点抑制剂疗法敏感性中的应用
CN116406377A (zh) * 2020-07-17 2023-07-07 基因泰克公司 抗notch2抗体及其使用方法
CN112625125B (zh) * 2021-01-18 2021-12-14 中国人民解放军军事科学院军事医学研究院 一株中和新型冠状病毒感染的单抗
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
WO2022272283A1 (en) * 2021-06-24 2022-12-29 H. Lee Moffitt Cancer Center And Research Institute Inc. Dual egfr-muc1 chimeric antigen receptor t cells
TW202340251A (zh) 2022-01-19 2023-10-16 美商建南德克公司 抗ｎｏｔｃｈ２抗體及結合物及其使用方法
CN118344474B (zh) * 2024-05-28 2024-11-15 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 口蹄疫病毒O型、A型和Asia1型广谱中和性猪源单克隆抗体及其应用

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6344321B1 (en) 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
DE122009000019I1 (de) 1991-04-25 2009-07-16 Chugai Seiyaku K K 5 1 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US20050112121A1 (en) 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
DE4425115A1 (de) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1996036361A1 (en) 1995-05-18 1996-11-21 The Regents Of The University Of Michigan Dna binding antibodies
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
CA2250394A1 (en) 1996-03-30 1997-10-09 Boehringer Mannheim Gmbh Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors
JP2000512134A (ja) 1996-05-31 2000-09-19 ザ ナショナル アメリカン レッド クロス Ｊａｇｇｅｄ／Ｎｏｔｃｈタンパク質および核酸に基づく治療および診断の方法および組成物
FR2751986B1 (fr) 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
CA2271248C (en) 1996-11-07 2009-08-11 Jonathan Robert Lamb Use of a notch ligand in immunotherapy
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6379925B1 (en) 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
WO1998057621A1 (en) 1997-06-18 1998-12-23 The Trustees Of Columbia University In The City Ofnew York Angiogenic modulation by notch signal transduction
US6692919B1 (en) 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
WO2003070984A1 (en) 2002-02-15 2003-08-28 Somalogic, Inc. Methods and reagents for detecting target binding by nucleic acid ligands
AU768269B2 (en) 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
US20030054360A1 (en) 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US20030003572A1 (en) 1999-03-05 2003-01-02 David J. Anderson Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
US20020010320A1 (en) 1999-04-05 2002-01-24 James W. Fett Chemeric and humanized antibodies to angiogenin
DE60044997D1 (de) 1999-07-02 2010-11-04 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20030031670A1 (en) 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
DE10031380A1 (de) 2000-06-28 2002-01-10 Merck Patent Gmbh Verfahren zur Übertragung von Alkyliden-Gruppen auf organischen Verbindungen
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20080194022A1 (en) 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
AU2001288628A1 (en) 2000-08-31 2002-03-13 Loyola University Chicago Method and reagents for treatment of skin disorders by modulating the notch pathway
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
EP2351855A1 (en) 2000-09-26 2011-08-03 Duke University RNA aptamers and methods for identifying the same
EP1322761A4 (en) 2000-10-02 2005-03-23 Korea Res Inst Of Bioscience HUMANIZED ANTIBODY AGAINST THE HEPATITE B VIRUS SURFACE ANTIGEN AND METHOD OF PREPARING THE SAME
ATE484522T1 (de) 2001-04-24 2010-10-15 Bayer Corp Menschliche antikörper gegen timp-1
US7356224B2 (en) 2001-07-03 2008-04-08 Brown University Research Foundation Method and apparatus for detecting multiple optical wave lengths
WO2003042246A2 (en) 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
CA2469204A1 (en) 2001-12-07 2003-06-19 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
GB0201674D0 (en) 2002-01-25 2002-03-13 Lorantis Ltd Medical treatment
JP2005530856A (ja) 2002-06-21 2005-10-13 ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン 膜関連腫瘍内皮マーカー
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
JP2006515747A (ja) 2002-11-01 2006-06-08 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
US20050124565A1 (en) 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
WO2004052389A2 (en) 2002-12-06 2004-06-24 Singapore General Hospital Pte Ltd. Nogo, caspr, f3 nb-3 useful in the treatment of injury and disease to the central nervous system
EP2060918A3 (en) 2003-04-01 2009-08-26 The Johns Hopkins University Breast endothelial cell expression patterns
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
WO2005024042A2 (en) 2003-09-04 2005-03-17 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
GB0321805D0 (en) 2003-09-18 2003-10-15 Univ Wales Medicine Human tumour growth patterns
WO2005054434A2 (en) 2003-11-26 2005-06-16 Health Research, Inc. Use of notch pathway interfering agents for treatment of plasma cell disorders
EP1718767B1 (en) 2004-02-03 2012-04-11 The Regents Of The University Of Michigan Compositions for treating breast and pancreatic cancer
FR2867784B1 (fr) 2004-03-17 2006-06-09 Commissariat Energie Atomique Aptameres selectionnes a partir de cellules vivantes tumorales et leurs applications
WO2005090981A2 (en) * 2004-03-24 2005-09-29 Technion Research & Development Foundation Ltd. Electrode
US20050239134A1 (en) 2004-04-21 2005-10-27 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
GB0421838D0 (en) 2004-09-30 2004-11-03 Congenia S R L Cancer markers
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
US20070265246A1 (en) 2004-11-10 2007-11-15 Clevers Johannes C Treatment of an Intestinal Adenoma and/or Adenocarcinoma by Inhibition of Notch Pathway Activation
US10538742B2 (en) 2004-11-12 2020-01-21 Cambridge Enterprise Limited Methods and means related to cancer stem cells
EP2083088A3 (en) 2005-04-07 2009-10-14 Novartis Vaccines and Diagnostics, Inc. Cancer-related genes
ES2360232T3 (es) 2005-06-29 2011-06-02 Compumedics Limited Conjunto sensor con puente conductor.
WO2007053648A2 (en) 2005-10-31 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007061988A2 (en) 2005-11-22 2007-05-31 University Of Vermont And State Agricultural College Methods for determining notch signaling and uses thereof
WO2007070671A2 (en) 2005-12-16 2007-06-21 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
WO2007075915A2 (en) 2005-12-22 2007-07-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies against orthopoxviruses
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
WO2008057144A2 (en) * 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
AU2007319672B2 (en) 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
US20080014196A1 (en) 2006-06-06 2008-01-17 Genentech, Inc. Compositions and methods for modulating vascular development
CA2655362A1 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
WO2008050525A1 (en) 2006-09-29 2008-05-02 Konica Minolta Opto, Inc. Retardation film
HUE028379T2 (en) 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
US7700113B2 (en) 2006-10-19 2010-04-20 Maine Medical Research Institute, A Division Of Maine Medical Center Inhibiting breast cancer cell growth by administering an intracellular domain of NOTCH2
CA2666179A1 (en) 2006-10-19 2008-11-13 Genentech, Inc. Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
CA2666672A1 (en) 2006-10-19 2008-05-02 Genentech, Inc. Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
WO2008057114A1 (en) 2006-11-06 2008-05-15 Howard Shapiro Management of teaching processes for individualized instruction in a multi-student environment
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
TWI419904B (zh) 2006-12-18 2013-12-21 Genentech Inc 拮抗劑抗-ｎｏｔｃｈ３抗體及其用於預防及治療ｎｏｔｃｈ３相關疾病之用途
EP2120996A2 (en) 2006-12-20 2009-11-25 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
AU2008209482B2 (en) 2007-01-24 2014-05-01 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008091222A1 (en) 2007-01-26 2008-07-31 Bioinvent International Ab Dll4 signaling inhibitors and uses thereof
US20090208491A1 (en) 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
WO2008109075A2 (en) * 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
JP2010520280A (ja) 2007-03-05 2010-06-10 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CN106432496B (zh) 2007-07-16 2020-02-07 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
BRPI0815291A2 (pt) 2007-08-23 2015-02-03 Univ Columbia "proteina de fusão, metodo de tratamento de pacientes que possuem um tumor, método de inibição da angiogênese em pacientes, método de tratamento de pacientes que possuem câncer do ovário, método de tratamento de pacientes que possuem um distúrbio metábolico, uso de proteína de fusão, método de inibição de linfoangiogênese patológica em pacientes, método de inibição da metástase de tumores em pacientes, método de inibição do crescimento de tumores secundários em pacientes, métodos de inibição da cooptação de vasos sanguineos por um tumor em pacientes, método de tratamento de cancer em pacientes e método de tratamento da retinopatia proliferativa vascular"
CA2697106A1 (en) 2007-08-28 2009-03-12 Donald Bergstrom Expression profiles of biomarker genes in notch mediated cancers
US7807630B2 (en) 2007-09-14 2010-10-05 Vanderbilt University Targeting of Notch3 receptor function for cancer therapy
WO2009035522A1 (en) 2007-09-14 2009-03-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US8834875B2 (en) 2010-01-13 2014-09-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
NZ590127A (en) 2008-07-08 2012-11-30 Oncomed Pharm Inc Notch1 receptor binding agents and methods of use thereof
PE20120080A1 (es) 2008-10-01 2012-02-17 Genentech Inc Anticuerpos anti-notch2 y metodos de uso
JP2012520325A (ja) 2009-03-13 2012-09-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プレバイオティックオリゴ糖
RU2012117619A (ru) 2009-09-30 2013-11-10 Дженентек, Инк. ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3
DE102009047243A1 (de) 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
WO2011100566A2 (en) 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
JP5450221B2 (ja) 2010-04-14 2014-03-26 株式会社神戸製鋼所 高電流密度ガスシールドアーク溶接方法
KR20200044999A (ko) 2010-05-04 2020-04-29 파이브 프라임 테라퓨틱스, 인크. Ｃｓｆ1ｒ에 결합하는 항체들
WO2012003472A1 (en) 2010-07-02 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies
PL2683406T3 (pl) 2011-03-11 2019-11-29 Beth Israel Deaconess Medical Ct Inc Przeciwciała anty-cd40 i ich zastosowania
CN104105702B (zh) 2011-11-16 2016-11-23 昂考梅德药品有限公司 人notch受体突变及其应用
WO2013173542A1 (en) 2012-05-16 2013-11-21 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch2/3 antibodies
WO2014039533A2 (en) 2012-09-04 2014-03-13 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
AU2013317886A1 (en) 2012-09-21 2015-04-09 Oncomed Pharmaceuticals, Inc. Methods of treating hematological malignancies with NOTCH1 antibodies
BR112015010436A2 (pt) 2012-11-07 2017-08-22 Pfizer Anticorpos anti-notch3 e conjugados anticorpo-fármaco
WO2014151606A2 (en) 2013-03-15 2014-09-25 Oncomed Pharmaceuticals, Inc. Methods of treating pancreatic cancer
WO2015134627A1 (en) 2014-03-07 2015-09-11 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch1 antibodies
WO2015153997A2 (en) 2014-04-04 2015-10-08 Oncomed Pharmaceuticals, Inc. Notch3 antibodies and uses thereof

Also Published As

Publication number Publication date
DOP2011000002A (es) 2011-04-15
US9499613B2 (en) 2016-11-22
BRPI0914007A2 (pt) 2015-11-17
US9505832B2 (en) 2016-11-29
MA32449B1 (fr) 2011-07-03
JP2012501625A (ja) 2012-01-26
US20120288496A1 (en) 2012-11-15
MY155603A (en) 2015-11-13
EA026109B1 (ru) 2017-03-31
PT2307051E (pt) 2015-05-21
US20170198031A1 (en) 2017-07-13
ES2531541T3 (es) 2015-03-17
US20100111958A1 (en) 2010-05-06
NZ590127A (en) 2012-11-30
US20130260455A1 (en) 2013-10-03
EA201170158A1 (ru) 2011-08-30
CN102316897B (zh) 2014-11-05
US8226943B2 (en) 2012-07-24
SMT201500047B (it) 2015-05-05
IL210222A0 (en) 2011-03-31
IL210221A0 (en) 2011-03-31
SMT201500120B (it) 2015-07-09
ME02069B (me) 2015-05-20
PT2307459E (pt) 2015-03-11
US20150197563A1 (en) 2015-07-16
CO6612253A2 (es) 2013-02-01
HRP20150443T1 (hr) 2015-05-22
US8435513B2 (en) 2013-05-07
US20140011271A1 (en) 2014-01-09
EA201170157A1 (ru) 2011-08-30
PL2307051T3 (pl) 2015-07-31
WO2010005567A3 (en) 2010-05-27
KR20110031315A (ko) 2011-03-25
PL2307459T3 (pl) 2015-05-29
US8425903B2 (en) 2013-04-23
EP2307051A2 (en) 2011-04-13
DK2307051T3 (en) 2015-04-20
AU2009269095A1 (en) 2010-01-14
EP2924051A1 (en) 2015-09-30
SG192468A1 (en) 2013-08-30
US8945874B2 (en) 2015-02-03
SI2307051T1 (sl) 2015-04-30
AU2009269095B2 (en) 2016-05-19
WO2010005566A2 (en) 2010-01-14
AU2009269096B2 (en) 2016-05-12
WO2010005566A3 (en) 2010-09-16
EP2899211A1 (en) 2015-07-29
AU2016216568A1 (en) 2016-09-01
KR101682490B1 (ko) 2016-12-05
MX2011000236A (es) 2011-02-24
SG192467A1 (en) 2013-08-30
WO2010005567A2 (en) 2010-01-14
EP2307459A2 (en) 2011-04-13
EP2307459B1 (en) 2015-01-07
CN102316897A (zh) 2012-01-11
RS53924B1 (sr) 2015-08-31
US20150166963A1 (en) 2015-06-18
US8945547B2 (en) 2015-02-03
CY1116195T1 (el) 2017-02-08
HRP20150256T1 (hr) 2015-04-10
US20170183405A1 (en) 2017-06-29
EP2307051B1 (en) 2015-02-11
CA2729306A1 (en) 2010-01-14
HK1151296A1 (en) 2012-01-27
CN104402998A (zh) 2015-03-11
IL210221A (en) 2014-02-27
MY159815A (en) 2017-02-15
US8945873B2 (en) 2015-02-03
CN102112490B (zh) 2014-10-22
RS53750B1 (sr) 2015-06-30
SI2307459T1 (sl) 2015-04-30
US20130296536A1 (en) 2013-11-07
JP5560271B2 (ja) 2014-07-23
ME02148B (me) 2015-10-20
ZA201009280B (en) 2012-04-25
CY1116230T1 (el) 2017-02-08
AU2009269096A1 (en) 2010-01-14
CA2729602A1 (en) 2010-01-14
ES2535614T3 (es) 2015-05-13
MA32448B1 (fr) 2011-07-03
EP2307051A4 (en) 2012-07-18
EP2307459A4 (en) 2012-07-18
CR20110069A (es) 2011-07-11
CO6390041A2 (es) 2012-02-29
IL210222A (en) 2016-05-31
ZA201100029B (en) 2012-03-28
DOP2011000004A (es) 2011-04-15
CN102112490A (zh) 2011-06-29
NZ590131A (en) 2012-10-26
US20110311552A1 (en) 2011-12-22
BRPI0914004A2 (pt) 2015-11-17
KR101640099B1 (ko) 2016-07-15
US20130280277A1 (en) 2013-10-24
JP2012501626A (ja) 2012-01-26
UA101672C2 (uk) 2013-04-25
JP5560270B2 (ja) 2014-07-23
US8980260B2 (en) 2015-03-17
KR20110028621A (ko) 2011-03-21
HK1151218A1 (en) 2012-01-27
DK2307459T3 (da) 2015-02-09
MX2011000233A (es) 2011-05-19

Similar Documents

Publication Publication Date Title
CA2729306C (en) Notch-binding agents and antagonists and methods of use thereof
AU2009269096B9 (en) Notch1 receptor binding agents and methods of use thereof
HK1151296B (en) Notch1 receptor binding agents and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140411

MKLA Lapsed

Effective date: 20200831